Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up – Should You Buy?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) gapped up before the market opened on Monday . The stock had previously closed at $14.61, but opened at $15.37. Ono Pharmaceutical shares last traded at $15.37, with a volume of 7,520 shares trading hands.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the company currently has an average rating of “Strong Buy”.

Ono Pharmaceutical Stock Up 5.2%

The company has a market capitalization of $7.22 billion, a PE ratio of 14.64 and a beta of 0.33. The company’s fifty day moving average is $14.33 and its 200-day moving average is $14.78. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.